Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Alendronic acid
Drug ID BADD_D00066
Description Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959].
Indications and Usage Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone[FDA Label][A959,A176750]. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min[FDA Label].
Marketing Status approved
ATC Code M05BA04
DrugBank ID DB00630
KEGG ID D07119
MeSH ID D019386
PubChem ID 2088
TTD Drug ID D09KLR
NDC Product Code Not Available
UNII X1J18R4W8P
Synonyms Alendronate | 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate | Aminohydroxybutane Bisphosphonate | MK-217 | MK 217 | MK217 | Alendronate Monosodium Salt, Trihydrate | Alendronate Sodium | Fosamax
Chemical Information
Molecular Formula C4H13NO7P2
CAS Registry Number 66376-36-1
SMILES C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Flatulence07.01.04.0020.000392%
Fluid retention14.05.06.002; 20.01.02.0030.000176%Not Available
Food allergy10.01.01.0120.000110%Not Available
Gait disturbance08.01.02.002; 15.03.05.013; 17.02.05.0160.001994%
Gallbladder disorder09.03.02.0010.000682%Not Available
Gastric cancer16.13.03.001; 07.21.02.0010.000110%Not Available
Gastric haemorrhage07.12.01.001; 24.07.02.0070.000088%
Gastric polyps16.05.03.001; 07.20.01.0030.000132%Not Available
Gastric ulcer07.04.03.0020.000405%
Gastritis07.08.02.0010.001404%
Gastritis erosive07.04.03.0030.000198%Not Available
Gastritis haemorrhagic07.08.02.002; 24.07.02.0080.000044%Not Available
Gastrooesophageal reflux disease07.02.02.0030.007330%
Gastrointestinal disorder07.11.01.0010.001365%Not Available
Gastrointestinal pain07.01.05.005--
Generalised anxiety disorder19.06.01.0040.000044%Not Available
Generalised oedema14.05.06.007; 08.01.07.0040.000044%
Gingival bleeding07.09.07.001; 24.07.02.0100.000616%Not Available
Gingival disorder07.09.13.0040.000770%Not Available
Gingival pain07.09.13.0100.000251%
Gingival recession07.09.13.0120.000317%Not Available
Gingival swelling07.09.13.0130.000110%Not Available
Glaucoma06.03.01.0020.000881%
Glomerulonephritis20.05.01.001; 10.02.01.0060.000044%Not Available
Glossodynia07.14.02.0010.000198%Not Available
Glucose tolerance impaired14.06.02.001; 05.06.02.0010.000308%
Goitre14.11.01.008; 05.02.01.0010.000330%Not Available
Gout15.01.06.001; 14.09.01.0010.000528%Not Available
Gouty arthritis15.01.06.004; 14.09.01.0040.000066%Not Available
Granuloma23.03.15.001; 08.01.05.0010.000176%Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 39 Pages